Patents by Inventor SEETHARAMAIAH SETTY SUDARSHAN NAREMADDEPALLI

SEETHARAMAIAH SETTY SUDARSHAN NAREMADDEPALLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
    Publication number: 20240122904
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: November 22, 2023
    Publication date: April 18, 2024
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Chennakrishnareddy GUNDALA
  • DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS
    Publication number: 20240100024
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 28, 2024
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Nagaraj Gowda
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20230167076
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: November 7, 2022
    Publication date: June 1, 2023
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways
    Publication number: 20230144653
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Application
    Filed: January 5, 2023
    Publication date: May 11, 2023
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
    Publication number: 20230110077
    Abstract: The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Application
    Filed: October 10, 2022
    Publication date: April 13, 2023
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways
    Patent number: 11560403
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 24, 2023
    Assignee: AURIGENE ONCOLOGY LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 11512060
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 29, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
    Patent number: 11465976
    Abstract: The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Grant
    Filed: August 1, 2020
    Date of Patent: October 11, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
    Patent number: 11274123
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 15, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDS
    Publication number: 20210379024
    Abstract: The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
    Type: Application
    Filed: March 13, 2019
    Publication date: December 9, 2021
    Inventors: Pottayil Govindan Nair SASIKUMAR, Muralidhara RAMACHANDRA, Seetharamaiah Setty Sudarshan NAREMADDEPALLI, Gundala Chennakrishnareddy
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20210198219
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Application
    Filed: March 4, 2021
    Publication date: July 1, 2021
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways
    Publication number: 20210139536
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases or disorders mediated by CD47.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 13, 2021
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 10961205
    Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: March 30, 2021
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators
    Publication number: 20200361880
    Abstract: The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (1) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Application
    Filed: August 1, 2020
    Publication date: November 19, 2020
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators
    Patent number: 10781189
    Abstract: The present invention relates to 1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: September 22, 2020
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20200199086
    Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.
    Type: Application
    Filed: March 2, 2020
    Publication date: June 25, 2020
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 10590093
    Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: March 17, 2020
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling
    Publication number: 20190218252
    Abstract: The present invention relates to compounds of formula (I), compositions, methods and uses involving the said formula (I) that inhibit CD47 signaling pathway. The present invention also relates to methods of making such compounds and their uses for the treatment of diseases oR disorders mediated by CD47.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
  • 1,2,4-Oxadiazole Derivatives as Immunomodulators
    Publication number: 20190144402
    Abstract: The present invention relates to methods of modulating an immune response mediated by a PD-1 signaling pathway and of treating a cancer or an infectious disease. A subject is administered a compound(s) or a pharmaceutically acceptable salt or pharmaceutically acceptable composition thereof of formula (I) In the ring Q is S or O. R1 substituents are an optionally substituted side chain of the amino acid Ser or Thr and R3 substituents are a side chain of the amino acids Asn, Asp, Gln, or Glu. R2 is hydrogen or —CO-Aaa and Aaa is Thr or Ser with a free, amidated or esterified C-terminus. R4 and R5 are independently hydrogen or absent. R6 is hydrogen, alkyl or acyl.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • 1,2,4-oxadiazole derivatives as immunomodulators
    Patent number: 10173989
    Abstract: The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R1 represents ?CH2OtBu or ?CH(CH3)OtBu, R3 represents ?CH2C(O)NHCPh3, ?CH2CH2C(O)NHCPh3, ?CH2C(O)OtBu, or ?CH2CH2C(O)OtBu, and Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with tbutyl; the base is triethylamine; and the solvent is tetrahydrofuran.
    Type: Grant
    Filed: September 24, 2017
    Date of Patent: January 8, 2019
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli